Saturna Capital Corp decreased its position in Agilent Technologies, Inc. (NYSE:A - Free Report) by 0.5% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 905,686 shares of the medical research company's stock after selling 4,780 shares during the quarter. Agilent Technologies accounts for 1.8% of Saturna Capital Corp's portfolio, making the stock its 20th largest position. Saturna Capital Corp owned about 0.32% of Agilent Technologies worth $134,476,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also bought and sold shares of the company. Crewe Advisors LLC boosted its position in Agilent Technologies by 114.8% during the 2nd quarter. Crewe Advisors LLC now owns 189 shares of the medical research company's stock valued at $25,000 after buying an additional 101 shares during the period. Livelsberger Financial Advisory bought a new position in shares of Agilent Technologies in the 3rd quarter worth about $28,000. Ridgewood Investments LLC purchased a new position in Agilent Technologies during the second quarter valued at $29,000. Ashton Thomas Securities LLC bought a new position in Agilent Technologies in the 3rd quarter worth about $31,000. Finally, Fortitude Family Office LLC lifted its stake in shares of Agilent Technologies by 68.3% in the third quarter. Fortitude Family Office LLC now owns 234 shares of the medical research company's stock worth $35,000 after buying an additional 95 shares in the last quarter.
Agilent Technologies Price Performance
A traded up $0.68 during midday trading on Wednesday, hitting $134.35. 1,103,090 shares of the company traded hands, compared to its average volume of 1,701,778. The company has a market capitalization of $38.60 billion, a price-to-earnings ratio of 27.90, a PEG ratio of 5.88 and a beta of 1.07. The business has a 50 day simple moving average of $139.17 and a two-hundred day simple moving average of $138.16. The company has a current ratio of 1.78, a quick ratio of 1.37 and a debt-to-equity ratio of 0.36. Agilent Technologies, Inc. has a 52-week low of $109.46 and a 52-week high of $155.35.
Agilent Technologies (NYSE:A - Get Free Report) last issued its quarterly earnings results on Wednesday, August 21st. The medical research company reported $1.32 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.26 by $0.06. Agilent Technologies had a return on equity of 25.26% and a net margin of 21.75%. The firm had revenue of $1.58 billion for the quarter, compared to analyst estimates of $1.56 billion. During the same period in the previous year, the company posted $1.43 earnings per share. The business's revenue was down 5.6% on a year-over-year basis. On average, equities analysts forecast that Agilent Technologies, Inc. will post 5.24 earnings per share for the current fiscal year.
Agilent Technologies Announces Dividend
The company also recently announced a quarterly dividend, which was paid on Wednesday, October 23rd. Shareholders of record on Tuesday, October 1st were given a $0.236 dividend. This represents a $0.94 dividend on an annualized basis and a yield of 0.70%. The ex-dividend date of this dividend was Tuesday, October 1st. Agilent Technologies's payout ratio is 19.50%.
Insider Activity at Agilent Technologies
In other Agilent Technologies news, SVP Dominique Grau sold 9,990 shares of the business's stock in a transaction on Thursday, September 26th. The shares were sold at an average price of $145.00, for a total value of $1,448,550.00. Following the completion of the transaction, the senior vice president now owns 40,011 shares in the company, valued at $5,801,595. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In related news, SVP Dominique Grau sold 9,990 shares of Agilent Technologies stock in a transaction that occurred on Thursday, September 26th. The shares were sold at an average price of $145.00, for a total value of $1,448,550.00. Following the completion of the transaction, the senior vice president now owns 40,011 shares in the company, valued at $5,801,595. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Padraig Mcdonnell sold 1,958 shares of the firm's stock in a transaction on Thursday, August 22nd. The shares were sold at an average price of $145.00, for a total transaction of $283,910.00. Following the completion of the sale, the chief executive officer now owns 24,118 shares in the company, valued at $3,497,110. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 11,995 shares of company stock worth $1,739,510.
Wall Street Analyst Weigh In
A has been the subject of a number of research reports. Barclays upped their target price on shares of Agilent Technologies from $135.00 to $145.00 and gave the company an "underweight" rating in a report on Tuesday, October 15th. Bank of America increased their target price on Agilent Technologies from $140.00 to $147.00 and gave the stock a "neutral" rating in a research report on Thursday, August 22nd. Evercore ISI boosted their price target on shares of Agilent Technologies from $135.00 to $145.00 and gave the stock an "in-line" rating in a research note on Tuesday, October 1st. Stifel Nicolaus reiterated a "buy" rating and set a $151.00 target price on shares of Agilent Technologies in a research report on Monday, August 26th. Finally, UBS Group upped their target price on shares of Agilent Technologies from $141.00 to $150.00 and gave the company a "neutral" rating in a research report on Thursday, August 22nd. One research analyst has rated the stock with a sell rating, five have given a hold rating and nine have issued a buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $144.36.
Check Out Our Latest Research Report on Agilent Technologies
Agilent Technologies Company Profile
(
Free Report)
Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.
Read More
Before you consider Agilent Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Agilent Technologies wasn't on the list.
While Agilent Technologies currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
